Insider Selling: Axon Enterprise, Inc. (NASDAQ:AXON) Insider Sells 8,182 Shares of Stock

Axon Enterprise, Inc. (NASDAQ:AXON) insider Jeffrey C. Kunins sold 8,182 shares of Axon Enterprise stock in a transaction on Monday, September 9th. The shares were sold at an average price of $364.86, for a total value of $2,985,284.52. Following the completion of the sale, the insider now directly owns 176,228 shares of the company’s stock, valued at approximately $64,298,548.08. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Axon Enterprise Stock Performance

Axon Enterprise stock traded down $5.04 during midday trading on Tuesday, reaching $359.35. 324,389 shares of the company’s stock were exchanged, compared to its average volume of 518,497. The company has a debt-to-equity ratio of 0.35, a quick ratio of 2.52 and a current ratio of 2.88. The stock’s 50-day simple moving average is $332.91 and its 200 day simple moving average is $312.13. The firm has a market cap of $27.16 billion, a price-to-earnings ratio of 104.80, a P/E/G ratio of 9.50 and a beta of 0.94. Axon Enterprise, Inc. has a 52 week low of $189.12 and a 52 week high of $378.89.

Axon Enterprise (NASDAQ:AXON) last announced its earnings results on Tuesday, August 6th. The biotechnology company reported $1.20 earnings per share for the quarter, topping analysts’ consensus estimates of $1.02 by $0.18. The company had revenue of $504.00 million for the quarter, compared to analyst estimates of $478.35 million. Axon Enterprise had a return on equity of 9.34% and a net margin of 16.06%. The firm’s quarterly revenue was up 34.5% compared to the same quarter last year. During the same quarter last year, the company earned $0.80 earnings per share. On average, analysts expect that Axon Enterprise, Inc. will post 1.79 earnings per share for the current fiscal year.

Institutional Trading of Axon Enterprise

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Sanctuary Advisors LLC bought a new position in shares of Axon Enterprise during the second quarter worth approximately $836,000. New Century Financial Group LLC bought a new position in Axon Enterprise during the 2nd quarter worth $334,000. Cetera Investment Advisers raised its holdings in Axon Enterprise by 11.8% in the 2nd quarter. Cetera Investment Advisers now owns 23,546 shares of the biotechnology company’s stock valued at $6,928,000 after acquiring an additional 2,479 shares in the last quarter. Truist Financial Corp lifted its position in shares of Axon Enterprise by 53.4% during the 2nd quarter. Truist Financial Corp now owns 6,467 shares of the biotechnology company’s stock valued at $1,903,000 after acquiring an additional 2,251 shares during the period. Finally, EP Wealth Advisors LLC grew its holdings in shares of Axon Enterprise by 18.3% during the 2nd quarter. EP Wealth Advisors LLC now owns 1,577 shares of the biotechnology company’s stock worth $464,000 after purchasing an additional 244 shares in the last quarter. Institutional investors and hedge funds own 79.08% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts recently commented on AXON shares. Bank of America initiated coverage on Axon Enterprise in a research report on Wednesday, July 17th. They set a “buy” rating and a $380.00 price target on the stock. Barclays boosted their target price on shares of Axon Enterprise from $381.00 to $387.00 and gave the company an “overweight” rating in a research note on Wednesday, August 7th. Northland Securities upped their price target on shares of Axon Enterprise from $330.00 to $365.00 and gave the stock an “outperform” rating in a research report on Thursday, August 8th. Jefferies Financial Group assumed coverage on Axon Enterprise in a report on Wednesday, July 17th. They set a “buy” rating and a $385.00 target price on the stock. Finally, Craig Hallum lifted their price objective on shares of Axon Enterprise from $370.00 to $376.00 and gave the stock a “buy” rating in a research note on Wednesday, August 7th. Two research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company. According to data from MarketBeat.com, Axon Enterprise presently has a consensus rating of “Moderate Buy” and an average price target of $361.15.

About Axon Enterprise

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.